ערך בספרים למניה: Skye Bioscience (SKYE)

Skye Bioscience, Inc. (SKYE) management is currently actively pivoting its strategy toward the weight loss drug market, which is fueling shareholder optimism. The business relies on external contractors for testing and product promotion. This daily price action on the GURU.Markets platform, visualized for analytical convenience, is currently at -0.11. Meanwhile, drug manufacturing has been outsourced to third-party plants, while the company's own laboratories remain in California.

Skye Bioscience, Inc. (SKYE) focuses on creating unique cannabinoid modifications to combat obesity, protecting its developments through FDA patents. The bps metric trend reflects the ratio of net equity to the number of shares, allowing for a real-time assessment of the actual asset value per share and the identification of hidden imbalances in the company's asset structure prior to the publication of official reports.